


What is claimed :

1. A compound having the molecular structure :

5



wherein R₃ is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and a moiety -C≡CR' (R' being hydrogen or C₁-C₆ lower alkyl);

10 wherein R₄ is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and cyanide;

wherein R_{17α} is selected from the group consisting of hydrogen, C₁-C₆ lower alkyl, C₂-C₆ lower alkenyl, and C₂-C₆ lower alkynyl, or R_{17α} and R_{17β} together are oxygen forming a keto group;


15 wherein R_{17β} is selected from the group consisting of hydroxyl and a group transformed on the skin into hydroxyl, or R_{17α} and R_{17β} together are oxygen forming a keto group;

wherein R_{16α} is selected from the group consisting of hydrogen, C₁-C₆ lower alkyl, C₂-C₆ lower alkenyl, and C₂-C₆ lower alkynyl;

20 wherein R_{16β} is selected from the group consisting of hydrogen, C₁-C₆ lower alkyl, C₂-C₆ lower alkenyl, and C₂-C₆ lower alkynyl;


wherein at least one of R₃ or R₄ is not an hydrogen.

2. The compound selected from the group consisting of :



4-cyano-16 α -methyl-16 β -ethyl-1,3,5(10)-estratrien-17 β -ol


and



5

4-cyano-16 α -methyl-16 β -ethyl-1,3,5(10)-estratrien-17-one

3. A pharmaceutical composition comprising a pharmaceutical acceptable diluent or carrier and a therapeutically acceptable amount of an antiandrogen having
10 the molecular structure :



wherein R₃ is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and a moiety -C≡CR' (R' being hydrogen or C1-C6 lower alkyl);

- 5 wherein R₄ is selected from the group consisting of hydrogen, fluoro, chloro, bromo, iodo, and cyanide;

wherein R₁₇_α is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl, or R₁₇_α and R₁₇_β together are oxygen forming a keto group;


- 10 wherein R₁₇_β is selected from the group consisting of hydroxyl and a group transformed on the skin into hydroxyl, or R₁₇_α and R₁₇_β together are oxygen forming a keto group;

wherein R₁₆_α is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl;

- 15 wherein R₁₆_β is selected from the group consisting of hydrogen, C1-C6 lower alkyl, C2-C6 lower alkenyl, and C2-C6 lower alkynyl;


wherein at least one of R₃, or R₄ is not an hydrogen.

4. A pharmaceutical composition comprising a pharmaceutical acceptable diluent or carrier and a therapeutically acceptable amount of an antiandrogen selected from the group consisting of :
- 20



4-cyano-16 α -methyl-16 β -ethyl-1,3,5(10)-estratrien-17 β -ol

and



5

4-cyano-16 α -methyl-16 β -ethyl-1,3,5(10)-estratrien-17-one

5. A method of treating or reducing the risk of developing, acne, seborrhea, hirsutism or androgenic alopecia, comprising administering to a patient in need of such treatment or reduction, a therapeutically effective amount of the compound of
10 claim 1
6. The method of claim 5, further comprising administering to said patient a therapeutically effective amount of an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase
- 15
7. The method of claim 5, further comprising administering to said patient a therapeutically effective amount of a 5 α -reductase inhibitor.

8. The method of Claim 5, further comprising administering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).
- 5
9. The method of Claim 6, further comprising administering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).
- 10
10. The method of claim 7, further comprising administering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).
- 15
11. The method of claim 5, further comprising administering to said patient a therapeutically effective amount of a 5 α -reductase inhibitor and an inhibitor of type 5 17 β -hydroxysteroid dehydrogenase.
- 20
12. The method of Claim 11, further comprising administering to said patient a therapeutically effective amount of an inhibitor of Prostate Short-Chain Dehydrogenase/Reductase 1 (PSDR1).